For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.The discovery of this relationship can be traced back to ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Semaglutide — the active substance in Ozempic and Wegovy — may help reduce alcohol cravings in people with alcohol use ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis ... development for the treatment of ...